头孢噻肟钠/舒巴坦钠治疗下呼吸道感染的疗效评价  

To evaluate the efficacy of cefotaxime/sulbactam in treatment of lower respiratory tract infections

作　　者：李复雄[1] 王晓川[1] 王自财[1] 黄明毅[1] 霍开秀[1] 

机构地区：[1]深圳市龙岗中心医院,广东深圳518116

出　　处：《临床医药实践》2004年第4期259-261,共3页Proceeding of Clinical Medicine

摘　　要：目的 :评价头孢噻肟钠 /舒巴坦钠治疗下呼吸道感染的临床疗效和安全性。方法 :70例下呼吸道感染患者随机分为两组 ,治疗组 (35例 )给予头孢噻肟钠 /舒巴坦钠 2 .5g ,静脉滴注 ,每日 2次 ,对照组 (35例 )给头孢噻肟钠 2 .0g ,静脉滴注 ,每日 2次 ,疗程均为 7d～ 14d。观察并比较两组临床疗效、不良反应和细菌清除率。结果 :治疗组临床痊愈率 80 .0 % ,总有效率 91.4 % ,细菌清除率 90 .0 % ;而对照组分别为 5 7.1%、6 8.6 %和 6 4 .3%。两组间差异均有显著性。两组不良反应发生率均为 2 .9%。结论 :头孢噻肟钠 /舒巴坦钠治疗下呼吸道细菌感染临床疗效优于头孢噻肟钠 ,是广谱、高效。Objective:To evaluate the efficacy and safety of cefotaxime/sulbactam in treatment of lower respiratory tract infections.Methods:70 patients were randoly divided into two groups:35 patients in the treatment group received cefotaxime/sulbactam 2.5 g bid,intravenous,35 patients in the control group received cefotaxime 2.0 g bid,intravenous,both for 7～14 days.The efficacy,adverse reactions and bacterial clearance rate of two groups were observed and evaluated.Results:The cure rate,effective rate and bacterial clearance rate of the treatment group were 80.0 %,91.4 % and 90.0 % respectively and those of control group were 57.1 %,68.6 % and 64.3 % respectively.There were statistically significant difference.The rate of adverse reactions for both groups were 2.9 %.Conclusion:Cefotaxime/sulbactam was better than cefotaxime in treatment of lower respiratory tract infections.It is a highly effective and safe antibiotic with broad antibacterial spectrum.

关 键 词：头孢噻肟钠 舒巴坦钠 药物治疗 下呼吸道感染 疗效 安全性 

分 类 号：R56[医药卫生—呼吸系统] R978.1[医药卫生—内科学]